Publications by Petr Ricanek
31 publications found
Original articles
Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study
Scand J Gastroenterol, 1-9 (in press)
DOI 10.1080/00365521.2024.2313056, PubMed 38356408
Symptoms and symptom clusters in patients newly diagnosed with inflammatory bowel disease: results from the IBSEN III Study
BMC Gastroenterol, 23 (1), 255
DOI 10.1186/s12876-023-02889-y, PubMed 37501083
Health-related quality of life in patients with newly diagnosed inflammatory bowel disease: an observational prospective cohort study (IBSEN III)
Qual Life Res, 32 (10), 2951-2964
DOI 10.1007/s11136-023-03435-9, PubMed 37219727
Analysis of Systemic Epigenetic Alterations in Inflammatory Bowel Disease: Defining Geographical, Genetic and Immune-Inflammatory influences on the Circulating Methylome
J Crohns Colitis, 17 (2), 170-184
DOI 10.1093/ecco-jcc/jjac127, PubMed 36029471
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
Scand J Gastroenterol, 58 (8), 874-882
DOI 10.1080/00365521.2023.2177884, PubMed 36788656
Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]
J Crohns Colitis, 16 (9), 1428-1435
DOI 10.1093/ecco-jcc/jjac050, PubMed 35380641
Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2
J Crohns Colitis, 16 (8), 1255-1268
DOI 10.1093/ecco-jcc/jjac033, PubMed 35212366
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy
Arthritis Rheumatol, 74 (8), 1321-1332
DOI 10.1002/art.42153, PubMed 35507355
Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort
Clin Exp Gastroenterol, 15, 5-25
DOI 10.2147/CEG.S343468, PubMed 35185343
Treatment and outcome of gastrointestinal bleeding due to peptic ulcers and erosions - (BLUE study)
Scand J Gastroenterol, 57 (1), 8-15
DOI 10.1080/00365521.2021.1988701, PubMed 34663154
Systemic Inflammation in Preclinical Ulcerative Colitis
Gastroenterology, 161 (5), 1526-1539.e9
DOI 10.1053/j.gastro.2021.07.026, PubMed 34298022
Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway
Scand J Gastroenterol, 56 (8), 899-905
DOI 10.1080/00365521.2021.1922746, PubMed 34154494
Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease
J Crohns Colitis, 15 (5), 699-708
DOI 10.1093/ecco-jcc/jjaa230, PubMed 33201212
Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel Disease
J Crohns Colitis, 14 (12), 1724-1733
DOI 10.1093/ecco-jcc/jjaa134, PubMed 32598439
Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character)
Scand J Gastroenterol, 55 (10), 1146-1156
DOI 10.1080/00365521.2020.1803396, PubMed 32780604
Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease - associations with disease phenotype, treatment, and outcome
Clin Exp Gastroenterol, 12, 37-49
DOI 10.2147/CEG.S186235, PubMed 30774408
Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland
QJM, 111 (12), 920-924
DOI 10.1093/qjmed/hcy193, PubMed 31222346
The prevalence and transcriptional activity of the mucosal microbiota of ulcerative colitis patients
Sci Rep, 8 (1), 17278
DOI 10.1038/s41598-018-35243-4, PubMed 30467421
Determinants of optimal bowel function in ileal pouch-anal anastomosis - physiological differences contributing to pouch function
Scand J Gastroenterol, 53 (1), 8-14
DOI 10.1080/00365521.2017.1390601, PubMed 29043868
Simultaneous purification of DNA and RNA from microbiota in a single colonic mucosal biopsy
BMC Res Notes, 9, 328
DOI 10.1186/s13104-016-2110-7, PubMed 27352784
Reduced expression of aquaporins in human intestinal mucosa in early stage inflammatory bowel disease
Clin Exp Gastroenterol, 8, 49-67
DOI 10.2147/CEG.S70119, PubMed 25624769
Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study
Expert Rev Gastroenterol Hepatol, 9 Suppl 1, 45-52
DOI 10.1586/17474124.2015.1091308, PubMed 26395534
Dominant fecal microbiota in newly diagnosed untreated inflammatory bowel disease patients
Gastroenterol Res Pract, 2013, 636785
DOI 10.1155/2013/636785, PubMed 24348539
Age-dependent fecal bacterial correlation to inflammatory bowel disease for newly diagnosed untreated children
Gastroenterol Res Pract, 2013, 302398
DOI 10.1155/2013/302398, PubMed 23690761
Gut bacterial profile in patients newly diagnosed with treatment-naïve Crohn's disease
Clin Exp Gastroenterol, 5, 173-86
DOI 10.2147/CEG.S33858, PubMed 23049264
Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers
Scand J Gastroenterol, 46 (9), 1081-91
DOI 10.3109/00365521.2011.584897, PubMed 21619483
Paucity of mycobacteria in mucosal bowel biopsies from adults and children with early inflammatory bowel disease
J Crohns Colitis, 4 (5), 561-6
DOI 10.1016/j.crohns.2010.05.003, PubMed 21122560
Review articles
"Out of the box" new therapeutic strategies for Crohn´s disease: moving beyond biologics
Rev Esp Enferm Dig, 115 (11), 614-634
DOI 10.17235/reed.2022.9010/2022, PubMed 35748460
Gastrointestinal bleeding due to peptic ulcers and erosions - a prospective observational study (BLUE study)
Scand J Gastroenterol, 55 (10), 1139-1145
DOI 10.1080/00365521.2020.1819405, PubMed 32931710
Other articles
Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor ACE2 and TMPRSS2 in Inflammatory Bowel Disease
Gastroenterology, 159 (3), 1151-1154.e2
DOI 10.1053/j.gastro.2020.05.030, PubMed 32413354
Considered "negative" for MAP, these results would be very "positive" for tuberculoid leprosy Reply
J. Crohns Colitis, 5 (4), 374
DOI 10.1016/j.crohns.2011.04.007